Segment Reporting - Summary of Significant Segment Expenses (Details) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | ||||
|---|---|---|---|---|---|---|
Jun. 30, 2026 |
Mar. 31, 2026 |
Jun. 30, 2025 |
Mar. 31, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
|
| Research and development expenses: | ||||||
| Clinical and development costs | $ 7,093 | $ 11,834 | $ 15,373 | $ 22,371 | ||
| Preclinical costs | 524 | 618 | 459 | 1,856 | ||
| Personnel and related costs | 3,455 | 3,582 | 6,630 | 11,145 | ||
| Stock-based compensation expense | 1,278 | 840 | 2,479 | 3,845 | ||
| Other research costs | 788 | 1,148 | 1,803 | 2,693 | ||
| Total research and development expenses | 13,138 | 18,022 | 26,744 | 41,910 | ||
| General and administrative expenses: | ||||||
| Personnel and related costs | 1,855 | 1,876 | 3,696 | 4,701 | ||
| Stock-based compensation expense | 1,405 | 1,296 | 2,713 | 3,507 | ||
| Other general and administrative costs | 1,873 | 2,279 | 4,084 | 5,175 | ||
| Total general and administrative expenses | 5,133 | 5,451 | 10,493 | 13,383 | ||
| Lease termination (gain) and impairment charge: | ||||||
| Lease termination (gain) and impairment charge | (238) | 3,175 | (238) | 3,175 | ||
| Total lease termination (gain) and impairment charge | (238) | 3,175 | (238) | 3,175 | ||
| Loss from operations | (18,033) | (26,648) | (36,999) | (58,468) | ||
| Interest income | 1,508 | 1,106 | 2,690 | 2,589 | ||
| Interest expense | (285) | (405) | (616) | (811) | ||
| Other expense, net | (257) | (2) | (69) | (13) | ||
| Loss on debt extinguishment | (904) | (904) | ||||
| Net loss | $ (17,971) | $ (17,927) | $ (25,949) | $ (30,754) | $ (35,898) | $ (56,703) |
| X | ||||||||||
- Definition Clinical and development costs. No definition available.
|
| X | ||||||||||
- Definition Gain (loss) lease termination and impairment charge. No definition available.
|
| X | ||||||||||
- Definition Lease Termination Gain and Impairment Charge No definition available.
|
| X | ||||||||||
- Definition Lease termination gain (loss) and impairment charge. No definition available.
|
| X | ||||||||||
- Definition Personnel and related costs in general and administrative expenses. No definition available.
|
| X | ||||||||||
- Definition Personnel and related costs in research and development expenses. No definition available.
|
| X | ||||||||||
- Definition Preclinical costs. No definition available.
|
| X | ||||||||||
- Definition Stock based compensation expense in general and administrative expenses. No definition available.
|
| X | ||||||||||
- Definition Stock based compensation expense in research and development expenses. No definition available.
|
| X | ||||||||||
- Definition Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of general and administrative expense classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of income (expense) related to nonoperating activities, classified as other. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of other research and development expense. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|